
Biotech pipelines keep advancing on cash reserves while a risk-off tech market tightens the financing outlook
Scribe, Vor, Akari and Incyte reported progress in Q4 2026, while a $1 trillion tech selloff signalled tighter risk appetite. Stockholm-listed BioArctic shows what commercial-stage income looks like. Every figure is traced to a filing, a press release or a dated event.








